Illumina, Inc. (ILMN) Position Boosted by Amalgamated Bank
Amalgamated Bank increased its position in Illumina, Inc. (NASDAQ:ILMN) by 55.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,176 shares of the life sciences company’s stock after acquiring an additional 6,092 shares during the period. Amalgamated Bank’s holdings in Illumina were worth $2,980,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. HPM Partners LLC raised its holdings in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after acquiring an additional 749,424 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. American Century Companies Inc. raised its holdings in Illumina by 276.9% in the 2nd quarter. American Century Companies Inc. now owns 475,111 shares of the life sciences company’s stock worth $82,441,000 after acquiring an additional 349,058 shares during the last quarter. Vanguard Group Inc. raised its holdings in Illumina by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after acquiring an additional 285,379 shares during the last quarter. Finally, Baird Financial Group Inc. raised its holdings in Illumina by 1,110.5% in the 1st quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock worth $47,629,000 after acquiring an additional 256,061 shares during the last quarter. Institutional investors own 93.34% of the company’s stock.
Shares of Illumina, Inc. (ILMN) traded down 0.15% on Friday, reaching $210.72. 942,620 shares of the company traded hands. The company has a 50-day moving average of $197.88 and a 200-day moving average of $180.42. The stock has a market capitalization of $30.77 billion, a price-to-earnings ratio of 42.28 and a beta of 0.81. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.04.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.86 earnings per share. Analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on ILMN. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective for the company in a report on Tuesday, June 27th. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $250.00 target price on shares of Illumina in a research note on Wednesday, August 2nd. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. Illumina presently has a consensus rating of “Hold” and an average price target of $181.76.
In other news, EVP Omead Ostadan sold 1,672 shares of Illumina stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $172.73, for a total value of $288,804.56. Following the sale, the executive vice president now owns 26,242 shares in the company, valued at $4,532,780.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the sale, the director now owns 534,176 shares in the company, valued at approximately $91,221,235.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 195,434 shares of company stock worth $37,480,647. 1.60% of the stock is owned by company insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.